Our data are not in contrast with the commonly accepted notion that Ipilimumab can block the action of CTLA-4 at the cell surface of T cells; this leads to a stronger immune anti-tumor response that according to previous report is the reason why Ipilimumab is working in patients with melanoma. The gene discussed is CTLA4; the disease is neoplasm.